Atalanta Therapeutics Secures USD 75 Million for Neurological Research
Deal News | Jan 28, 2025 | PR Newswire Cision EQT
EQT Life Sciences has led a USD 75 million Series B funding round in Atalanta Therapeutics, a Boston-based biotechnology firm pioneering the use of RNA interference (RNAi) as a therapeutic approach for neurological diseases. The funding will advance Atalanta's RNAi therapies for KCNT1-related epilepsy and Huntington's disease, moving them towards Phase 1 clinical trials. The financing was co-led by Sanofi Ventures and included participation from RiverVest Venture Partners, abrdn, Mirae Asset Financial Group, and F-Prime Capital. This investment marks a significant endorsement of Atalanta's innovative technology, aiming at silencing disease-promoting genes in previously unreachable areas of the brain and spinal cord. The Series B financing brings Atalanta's total capital from financings and partnerships to USD 240 million. Key figures include Atalanta’s CEO Alicia Secor and EQT Life Sciences’ Managing Director Arno de Wilde, both of whom expressed optimism about the potential impact on treating severe neurological disorders.
Sectors
- Biotechnology
- Life Sciences
- Venture Capital
Geography
- United States – Atalanta Therapeutics is based in Boston, USA, and is the target company receiving the Series B funding.
- Sweden – EQT Life Sciences, part of EQT based in Stockholm, Sweden, led the funding round.
Industry
- Biotechnology – Atalanta Therapeutics operates within the biotechnology industry, focusing on developing RNAi-based treatments for neurological diseases.
- Life Sciences – EQT Life Sciences, part of the investment group leading the funding round, operates within this sector, specializing in healthcare and life sciences investments.
- Venture Capital – The article discusses a Series B funding round led by various venture capital participants, including EQT Life Sciences and Sanofi Ventures.
Financials
- USD 75 million – The amount raised in the Series B funding round led by EQT Life Sciences for Atalanta Therapeutics.
- USD 240 million – Total capital generated by Atalanta Therapeutics from financings and partnerships to date.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Atalanta Therapeutics | Target Company | Company | A biotechnology firm developing RNAi-based therapies for neurological diseases. |
| EQT Life Sciences | Leading Investor | Company | Part of EQT based in Stockholm, Sweden, specializing in investments in the life sciences sector. |
| Sanofi Ventures | Co-Leading Investor | Company | A venture capital arm of Sanofi focusing on investing in biopharma and digital health innovations. |
| RiverVest Venture Partners | Investor | Company | A venture capital firm investing in early-stage life sciences companies. |
| abrdn, Inc. | Investor | Company | Global asset management company participating as an investor in the Series B round. |
| Mirae Asset Financial Group | Investor | Company | A global financial group investing in the Series B funding. |
| F-Prime Capital | Investor | Company | A venture capital firm with a focus on healthcare and technology sectors, existing investor in Atalanta. |
| Alicia Secor | CEO | Person | President and CEO of Atalanta Therapeutics, overseeing the company's strategic vision and operations. |
| Arno de Wilde | Managing Director | Person | Managing Director at EQT Life Sciences involved in leading the investment in Atalanta Therapeutics. |